{"id":"W3204626226","doi":"10.1016/j.euf.2021.07.018","title":"Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non–muscle-invasive bladder cancer: Pro","year":2021,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Astellas Pharma; UroGen Pharma; AbbVie; Sanofi; Merck; Bayer; AstraZeneca; Pfizer","keywords":"Medicine; Gemcitabine; Docetaxel; Bladder cancer; Oncology; Urology; Second-line therapy; Standard of care; Internal medicine; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003971618,0.0004344051,0.0006435403,0.00008903872,0.0002957214,0.00005621266,0.0002757809,0.0001415137,0.002788934],"category_scores_gemma":[0.0001907121,0.0002968353,0.0003526447,0.000245403,0.0003545598,0.00008012068,0.0001356835,0.0005070074,0.0001318103],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000154423,"about_ca_system_score_gemma":0.001309821,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004407921,"about_ca_topic_score_gemma":0.0001733832,"domain_scores_codex":[0.9972245,0.0004705629,0.0004864774,0.0008044995,0.0003342232,0.0006797314],"domain_scores_gemma":[0.9979919,0.0003429799,0.0001742275,0.0007173864,0.0005344722,0.0002390851],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0793865,0.002510652,0.004077615,0.0004386338,0.01497531,0.01268705,0.02871534,0.0002023152,0.1571968,0.002463901,0.249611,0.4477348],"study_design_scores_gemma":[0.05072825,0.0134658,0.03551972,0.0001131507,0.002167521,0.001036783,0.0007080864,0.000194185,0.2273649,0.001457895,0.6661387,0.001105032],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8796993,0.01501422,0.004216505,0.0724304,0.002055898,0.004327323,0.002110045,0.0002486769,0.01989758],"genre_scores_gemma":[0.9711273,0.001265269,0.0004360898,0.01898343,0.001935113,0.0002551669,0.0001023494,0.000156556,0.005738768],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4466298,"threshold_uncertainty_score":0.9999484,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03189313507915331,"score_gpt":0.3081511934025167,"score_spread":0.2762580583233634,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}